CN1082546A - 7-新戊基黄嘌呤衍生物,它们的制备和包含有它们的药物组合物 - Google Patents
7-新戊基黄嘌呤衍生物,它们的制备和包含有它们的药物组合物 Download PDFInfo
- Publication number
- CN1082546A CN1082546A CN93107615.3A CN93107615A CN1082546A CN 1082546 A CN1082546 A CN 1082546A CN 93107615 A CN93107615 A CN 93107615A CN 1082546 A CN1082546 A CN 1082546A
- Authority
- CN
- China
- Prior art keywords
- methyl
- neo
- pentyl
- xanthine
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
- TUWQUNCINNQYTG-UHFFFAOYSA-N 7-(2,2-dimethylpropyl)-3h-purine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=CN2CC(C)(C)C TUWQUNCINNQYTG-UHFFFAOYSA-N 0.000 title claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 55
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 18
- 230000002503 metabolic effect Effects 0.000 claims abstract description 7
- 239000002243 precursor Substances 0.000 claims abstract description 7
- 125000003118 aryl group Chemical group 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract description 3
- -1 isobutyl- Chemical group 0.000 claims description 34
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 10
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 208000014181 Bronchial disease Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- RXNKGKNAGQRIBK-UHFFFAOYSA-N 7-(2,2-dimethylpropyl)-1,3-dimethylpurine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(C)(C)C)C=N2 RXNKGKNAGQRIBK-UHFFFAOYSA-N 0.000 claims description 3
- ATDPBUXMNPNXPM-UHFFFAOYSA-N 7-(2,2-dimethylpropyl)-1-methyl-3h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)NC2=C1N(CC(C)(C)C)C=N2 ATDPBUXMNPNXPM-UHFFFAOYSA-N 0.000 claims description 3
- 229940075420 xanthine Drugs 0.000 claims description 3
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims description 2
- YQODZBUDFADLLI-UHFFFAOYSA-N 7-(2,2-dimethylpropyl)-1,8-dimethyl-3h-purine-2,6-dione Chemical compound N1C(=O)N(C)C(=O)C2=C1N=C(C)N2CC(C)(C)C YQODZBUDFADLLI-UHFFFAOYSA-N 0.000 claims description 2
- QHOFEQXLCBCTCB-UHFFFAOYSA-N 7-(2,2-dimethylpropyl)-1-methyl-3-phenylpurine-2,6-dione Chemical compound C1=2N=CN(CC(C)(C)C)C=2C(=O)N(C)C(=O)N1C1=CC=CC=C1 QHOFEQXLCBCTCB-UHFFFAOYSA-N 0.000 claims description 2
- ATOJIAQESPGOTE-UHFFFAOYSA-N 7-(2,2-dimethylpropyl)-3-methylpurine-2,6-dione Chemical compound O=C1NC(=O)N(C)C2=C1N(CC(C)(C)C)C=N2 ATOJIAQESPGOTE-UHFFFAOYSA-N 0.000 claims description 2
- ZBCKEBLXFQHMIE-UHFFFAOYSA-N 7-(2,2-dimethylpropyl)-8-methyl-3h-purine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=C(C)N2CC(C)(C)C ZBCKEBLXFQHMIE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002841 Lewis acid Substances 0.000 claims description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 2
- 150000001447 alkali salts Chemical class 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 150000004678 hydrides Chemical class 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 150000007517 lewis acids Chemical class 0.000 claims description 2
- 239000003444 phase transfer catalyst Substances 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 230000000694 effects Effects 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000009079 Bronchial Spasm Diseases 0.000 description 3
- 206010006482 Bronchospasm Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960000278 theophylline Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 201000009267 bronchiectasis Diseases 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- QLZYLBHFANJARQ-UHFFFAOYSA-N 3-benzyl-1-methyl-7h-purine-2,6-dione Chemical compound C1=2N=CNC=2C(=O)N(C)C(=O)N1CC1=CC=CC=C1 QLZYLBHFANJARQ-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940055858 aluminum chloride anhydrous Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000013502 data validation Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001844 tubocurarine Drugs 0.000 description 1
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及式(I)所代表的一类7-新戊基黄嘌
呤衍生物,
其中R1=H;直链或支链C1-6烷基或其取代烷基;苄
基或取代苄基;R3和R8可以相同或不同,分别是H;
直链或支链C1-6烷基或其取代烷基;苄基或取代苄
基;芳基或取代芳基;及其代谢前体化合物和它们的
药用盐,包括它们的制备和由它们组成的药物组合
物。
Description
本发明涉及式(Ⅰ)所示的7-新戊基衍生物类化合物
其中,R1=H;可任选取代的直链或支链C1-6烷基;可任选取代的苄基;R3和R8,可以相同或不同,分别是H;可任选取代的直链或支链C1-6烷基;可任选取代的苄基,可任选取代的芳基;它们的代谢前体化合物及其式(Ⅰ)化合物的药用盐,它们都具有与茶碱类似的活性,并且适用于治疗支气管痉挛。
人们很久以前就已经认识到取代黄嘌呤的支气管扩张效应。最近,进行了几项调查研究,旨在挑选出比茶碱有更佳的活性和选择性的黄嘌呤衍生物。
文献已报道了各种取代的黄嘌呤衍生物,以及它们的药物活性,如,美国专利NO.4,544,566(1985.10.1)。
现在已发现在氮7位上有新戊基取代的黄嘌呤衍生物能产生支气管扩张效应,这一活性可以与上文提到的专利中所报到的类似物相比美。本发明的化合物不产生任何中枢兴奋作用,因此,可以有效地用于治疗气喘。
另外,本发明所述化合物-与黄嘌呤类似物相比-具有惊人的长效药物作用活性。
具体地说,本发明包括式(Ⅰ)所代表的黄嘌呤衍生物。
其中,R1=H;可取代的支链或直链C1-6烷基;取代的苄基或苄基;R3和R8,可以相同或不同,分别是H;可取代的直链或支链C1-6烷基;苄基或取代苄基,芳基或取代芳基;及其代谢前体化合物和式(Ⅰ)化合物的药用盐。根据本发明,较好的直链或支链C1-6基团是;甲基,乙基,丙基,丁基,异丁基,仲丁基,和2-甲基丁基。
芳基最好是苯基。
较好的取代基团是;羟基,卤素,C1-C3烷氧基。很显然,从通式(Ⅰ)可知,如果分子中含有一个或多个手性中心,本发明也包含了由此衍生出来的对映异构体和/或非对映异构体。
根据本发明,更佳的产物是:
1-甲基-3-甲基-7-新戊基-黄嘌呤(式(Ⅰ)所示化合物,其中,R1=甲基;R3=甲基;R8=H);
1-甲基-3-苄基-7-新戊基-黄嘌呤(式(Ⅰ)所示化合物,其中R1=甲基;R3=苄基;R8=H);
1-甲基-7-新戊基-黄嘌呤(式(Ⅰ)所示化合物,其中,R1=甲基,R3=R8=H);
1-正丙基-3-苯基-7-新戊基-黄嘌呤(式(Ⅰ)所示化合物,其中,R1=正丙基;R3=苯基;R8=H);
1-甲基-3甲基-7-新戊基-8-甲基-黄嘌呤(式(Ⅰ)所示化合物,其中,R1=R3=R8=甲基);
1-甲基-3-异丁基-7-新戊基-黄嘌呤(式(Ⅰ)所示化合物,其中,R1=甲基;R3=异丁基;R8=H);
3-(2-甲基)丁基-7-新戊基-8-正丙基-黄嘌呤(式(Ⅰ)所示化合物,其中,R1=H;R3=(2-甲基)丁基;R8=正丙基);
3-甲基-7-新戊基-黄嘌呤(式(Ⅰ)所示化合物,其中,R1=H;R3=甲基;R8=H);
3-正丙基-7-新戊基-黄嘌呤(式(Ⅰ)所示化合物,其中,R1=H;R3=正丙基;R8=H);
1-甲基-3-(2-甲基)丁基-7-新戊基-8-甲基-黄嘌呤(式(Ⅰ)所示化合物,其中,R1=甲基;R3=(2-甲基)丁基;R8=甲基);
1-甲基-3-苯基-7-新戊基-黄嘌呤(式(Ⅰ)所示化合物,其中R1=甲基;R3=苯基;R8=H);
1-正丙基-3-(2-甲基)丁基-7-新戊基-8-甲基-黄嘌呤(通式(Ⅰ)化合物,其中R1=正丙基;R3=(2-甲基)丁基;R8=甲基);
1-正丙基-3-甲基-7-新戊基-黄嘌呤(式(Ⅰ)所示化合物,其中R1=正丙基、R3=甲基;R8=H;)
1-新戊基-7-新戊基-黄嘌呤(式(Ⅰ)所示化合物,其中R1=新戊基;R3=R8=H)
1-甲基-7-新戊基-8-甲基-黄嘌呤(式(Ⅰ)所示化合物,其中,R1=R8=甲基;R3=H)
1-甲基-3-(3-羧基-丙酰氧)甲基-7-新戊基-黄嘌呤(式(Ⅰ)所示化合物,其中R1=CH3;R8=H;R8=3-羧基-丙酰氧-甲基)
本发明的化合物可以通过式(Ⅱ)所示化合物的碱性盐
(其中R1,R3,R8与上文定义相同,R3=H除外)与新戊基卤在适当的溶剂中反应而得到。
所述式(Ⅰ)化合物的代谢前体化合物是指这样一类化合物,它们在被服用后,可被转化为显示药理活性的式(Ⅰ)化合物,根据上述意义,举例来说,代谢前体化合物是式(Ⅰ)化合物(R3=H)的相应的N-酰基-衍生物(如3-羧基-丙酰基-)或N-酰氧甲基-衍生物,(如N,N-二甲基甘氨酰氧甲基或3-羧基-丙酰氧-甲基)。
式(Ⅰ)所示化合物(R3=H)可以由对应的N3-苄基衍生物在适当的溶剂(如苯,甲苯,氯仿,二氯甲烷,等等)中通过催化还原或用路易斯酸(如无水氯化铝)处理,而高收率地得到,或者通过对应的N3-苄基衍生物的催化脱苄得到。
如果本发明的化合物在R1或R3上有烷基或苄基存在,它们可以从相应的未取代衍生物开始,用氢氧化物或氢化物盐化,并在适当的溶剂中用烷基卤或苄基卤处理得到。
式(Ⅰ)所示化合物最后可以通过式(Ⅱ)化合物(此处R3不是H)与新戊基卤在相转移催化剂存在下反应得到。
本发明所涉及的化合物或它们的药用盐(如果式(Ⅰ)中R3=H,最好是该化合物的钠盐或钾盐)可以作为适当的药物组合物,通过口服、直肠、非肠胃、吸服。或经皮给药等途径给药。该药物组合物,可以包含赋形剂,其存在形式可以是片剂,小瓶,糖浆,滴剂,气雾剂,栓剂,凝胶,软膏,缓释制剂,等等。
服药剂量明显地依赖于所用化合物本身,给药途径,和治疗对象,在各种情况下根据常见具体指标而选用。例如,对于人来说,口服本发明的化合物的剂量范围是100~1500毫克时,结果比较满意。
实例1.
1-甲基-3-甲基-7-新戊基-黄嘌呤
将茶碱(18克,0.1mols)溶于N,N-二甲基甲酰胺(200ml)中,加入在石蜡油中的50%NaH(4.8克,0.1mols)。大约半小时过后,滴入新戊基溴(15.2g;0.1mols),并将所得混和物130℃加热8小时。
真空蒸除溶剂,把残余物溶于水并用二氯甲烷萃取。
有机层浓缩至干,所得残渣用环己烷结晶,熔点为120°~121℃。
产物的化学结构通过元素分析和NMR数据得到证明。
1-甲基-3-苄基-7-新戊基-黄嘌呤
将1-甲基-3-苄基-黄嘌呤(16.4g,0.04mols)溶于N,N-二甲基甲酰胺中(160ml),加入50%NaH(1.8g)使之成盐,并加入新戊基溴(6.04g;0.04mols)。所得混和物在130℃加热6小时,蒸除溶剂,残渣溶于水并用二氯甲烷萃取。
有机层浓缩至干,残渣用异丙醚溶解,并过滤,得到目的化合物,熔点109-111℃。
1-甲基-7-新戊基-黄嘌呤
方法A(用Pd/C催化还原)
1-甲基-3-苄基-7-新戊基-黄嘌呤(4g)溶于冰醋酸(100ml)中,加入10%Pd/C(2g),并在60℃和3个大气压下氢化。
5小时后氢化完全;过滤出溶剂并蒸发至干。残余物用乙醚溶解,过滤,并溶于稀的NaOH溶液。
过滤所得混和物,并用0.1N盐酸沉淀,得到目的化合物,熔点209-211℃
方法B(用AlCl3处理)
向在甲苯(50ml)中的1-甲基-3-苄基-7-新戊基-黄嘌呤(8g)溶液中,在冷却和搅拌下加入无水AlCl3(8g)。所得溶液在60℃搅拌1小时,加入冷水,并搅拌2小时,真空下过滤得到目的化合物。溶点209-211℃
元素分析和NMR数据核实了化学结构。
生物活性
急性病毒
给18小时禁食的瑞士雄鼠(体重20g)口服本发明的化合物。连续6天记录给药后的症状,并根据Lichtfield和Wilcoxon的方法(J.Pham.Expt.Ther.,96,99,1949)计算出LD50。
抗支气管痉挛活性
对乙酰氯诱导的麻醉豚鼠的支气管痉挛的拮抗作用。
已被麻醉的豚鼠(体重300-350g)用d-管箭毒碱3mg/kg,静脉注射处理,并且用人工方法通过气泵使之每分钟换气60次。
该化合物通过口服途径给药,并且在给药后的0,1,3,和5小时后分别通过颈静脉注射乙酰氯(25μg/kg,静脉注射)。实验所得数据非常令人满意。
Claims (11)
2、权利要求1的衍生物,其中C1-6烷基选自下组基团;甲基,乙基,丙基,丁基,异丁基,仲丁基,2-甲基丁基;芳基是苯基;并且取代基选自羟基,卤素,C1-C3烷氧基。
3、权利要求1的衍生物,选自下列化合物:
1-甲基-3-甲基-7-新戊基-黄嘌呤,
1-甲基-3-苄基-7-新戊基-黄嘌呤,
1-甲基-7-新戊基-黄嘌呤,
1-正丙基-3苯基-7-新戊基-黄嘌呤,
1-甲基-3-甲基-7-新戊基-8-甲基-黄嘌呤,
1-甲基-3-异丁基-7-新戊基-黄嘌呤,
3-(2-甲基)丁基-7-新戊基-8-正丙基-黄嘌呤,
3-甲基-7-新戊基-黄嘌呤,
3-正丙基-7-新戊基-黄嘌呤,
1-甲基-3-(2-甲基)丁基-7-新戊基-8-甲基-黄嘌呤,
1-甲基-3-苯基-7-新戊基-黄嘌呤,
1-正丙基-3-(2-甲基)丁基-7-新戊基-8-甲基-黄嘌呤
1-正丙基-3-甲基-7-新戊基-黄嘌呤,
1-新戊基-7-新戊基-黄嘌呤,
1-甲基-7-新戊基-8-甲基-黄嘌呤,
1-甲基-3-(3-羧基-丙酰氧)甲基-7-新戊基-黄嘌呤。
4、1-甲基-7-新戊基-黄嘌呤钠盐和钾盐。
5、药物组合物,包括权利要求3的产物作为活性组分与适当的赋形剂。
7、制备式(Ⅰ)化合物(R3=H)的方法,包括对应的N3-苄基衍生物的催化脱苄。
8、制备式(Ⅰ)化合物(R3=H)的方法,包括:在适当的溶剂中用无水路易斯酸处理对应的N3-苄基衍生物。
9、制备在R1或R3位含有烷基或苄基的式(Ⅰ)化合物的方法,包括:用氢氧化物或氢化物盐化对应的未取代衍生物,然后在适当的溶剂中使所得化合物与烷基卤或苄基卤反应。
10、制备式(Ⅰ)化合物的方法,包括:式(Ⅱ)所示黄嘌呤(此处R3不是H)与新戊基卤在相转移催化剂存在下反应。
11、治疗支气管疾病的方法,包括给患者服用有效剂量的权利要求1中所述化合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITFI920134A IT1258944B (it) | 1992-06-22 | 1992-06-22 | Derivati 7-neopentil xantinici, loro preparazione e composizioni farmaceutiche che li contengono |
ITFI92A000134 | 1992-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1082546A true CN1082546A (zh) | 1994-02-23 |
Family
ID=11350146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN93107615.3A Pending CN1082546A (zh) | 1992-06-22 | 1993-06-22 | 7-新戊基黄嘌呤衍生物,它们的制备和包含有它们的药物组合物 |
Country Status (4)
Country | Link |
---|---|
CN (1) | CN1082546A (zh) |
AU (1) | AU4323493A (zh) |
IT (1) | IT1258944B (zh) |
WO (1) | WO1994000452A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11505241A (ja) * | 1995-05-19 | 1999-05-18 | カイロサイエンス・リミテッド | キサンチン類およびこれらの治療的使用 |
GB9623859D0 (en) * | 1996-11-15 | 1997-01-08 | Chiroscience Ltd | Novel compounds |
DE19816857A1 (de) * | 1998-04-16 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH654008A5 (fr) * | 1979-05-22 | 1986-01-31 | Nestle Sa | Procede de preparation de 1,3,7-trialkylxanthines. |
IT1200944B (it) * | 1982-08-10 | 1989-01-27 | Malesci Sas | Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico |
-
1992
- 1992-06-22 IT ITFI920134A patent/IT1258944B/it active IP Right Grant
-
1993
- 1993-06-07 AU AU43234/93A patent/AU4323493A/en not_active Abandoned
- 1993-06-07 WO PCT/EP1993/001434 patent/WO1994000452A1/en active Application Filing
- 1993-06-22 CN CN93107615.3A patent/CN1082546A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO1994000452A1 (en) | 1994-01-06 |
ITFI920134A0 (it) | 1992-06-22 |
ITFI920134A1 (it) | 1993-12-22 |
AU4323493A (en) | 1994-01-24 |
IT1258944B (it) | 1996-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI91760C (fi) | Menetelmä terapeuttisesti käyttökelpoisten 7-substituoitujen asetamido-3-alkenyyli-3-kefeemijohdannaisten valmistamiseksi | |
JPH04327587A (ja) | 6’−c−アルキル−3−デアザネプラノシンa誘導体、その製造法およびその用途 | |
US4532344A (en) | Fluoranthene derivatives | |
JPH06279470A (ja) | グアニジンアルキル−1,1−ビスホスホン酸誘導体、その製法およびその使用 | |
EP0353358A1 (en) | Bis(methylenedioxy)biphenyl compounds | |
CN1082546A (zh) | 7-新戊基黄嘌呤衍生物,它们的制备和包含有它们的药物组合物 | |
CN101076536A (zh) | β-核苷的立体选择性合成 | |
KR920002298B1 (ko) | 샤르트류신 유도체 또는 그염의 제조방법 | |
EP0028778B1 (en) | Antibacterial compositions comprising a beta-lactam-type compound and a 3-substituted propenoate | |
CN1617883A (zh) | 苯并氮杂环庚三烯化合物的固体盐及其在制备药物化合物中的应用 | |
CN1103762C (zh) | 新的具有抗惊厥活性且4-位上含有二取代氨基的1-芳(烷)基咪唑啉-2-酮类化合物,以及它们的制备方法 | |
US4585589A (en) | Water-soluble alkanoyloxy and alkoxycarbonyloxy rifampicin derivatives, process for its preparation, intermediates, and its pharmaceutical composition as antibacterials | |
CN1136204C (zh) | 2-咪唑啉-5-酮杀真菌剂的制备方法 | |
EP0117959A2 (fr) | Nouveaux dérivés de la nitrosourée, leur procédé de préparation et les compositions pharmaceutiques les renfermant | |
WO2009074253A2 (en) | Clofarabine phospholipid derivatives | |
JP2006520359A (ja) | ヌクレオチド脂質エステル誘導体 | |
AU634921B2 (en) | Deacetylcolchicine derivatives | |
US5250735A (en) | 2-(N-substituted-aminoalkyl)-5-(E)-alkylidene cyclopentanones, 2-(N-substituted-aminoalkyl)-5-(E)-arylalkylidene cyclopentanones, and derivatives thereof | |
CN1039813C (zh) | 具抗癌效应的顺式-二氨-1,1-环戊二羧酸根合铂(ⅱ)的化合物及其合成方法 | |
GB1580001A (en) | Therapeutically active 1 - phenyl - 1 - methoxy - 2-aminothane derivatives | |
EP0378706B1 (en) | 5-substituted uridine derivatives and intermediates for their preparation | |
CN1524864A (zh) | 一种双磷酸盐及其药用制剂的制备和用途 | |
SK279571B6 (sk) | Spôsob čistenia oxytetracyklínu a medziprodukt toh | |
EP0412015B1 (fr) | Nouveaux dérivés N-(vincristinoyl-23) et N-(noranhydro-5' vinblastinoyl-23) d'acide amino-1 méthylphosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
KR840000912B1 (ko) | 2, 4-디아미노-5-설파모일 벤젠 설폰산의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |